Abstract:Among the players of the adaptive response of cancer cells able to promote a resistant and aggressive phenotype, carbonic anhydrase IX (CAIX) recently has emerged as one of the most relevant drug targets. Indeed, CAIX targeting has received a lot of interest, and selective inhibitors are currently under clinical trials. Hypoxia has been identified as the master inductor of CAIX, but, to date, very few is known about the influence that another important characteristic of tumor microenvironment, i.e., extracellular acidosis, exerts on CAIX expression and activity. In the last decades, acidic microenvironment has been associated with aggressive tumor phenotype endowed with epithelial-to-mesenchymal transition (EMT) profile, high invasive and migratory ability, apoptosis, and drug resistance. We demonstrated that melanoma, breast, and colorectal cancer cells transiently and chronically exposed to acidified medium (pH 6.7 ± 0.1) showed a significantly increased CAIX expression compared to those grown in standard conditions (pH 7.4 ± 0.1). Moreover, we observed that the CAIX inhibitor FC16-670A (also named SLC-0111, which just successfully ended phase I clinical trials) not only prevents such increased expression under acidosis but also promotes apoptotic and necrotic programs only in acidified cancer cells. Thus, CAIX could represent a selective target of acidic cancer cells and FC16-670A inhibitor as a useful tool to affect this aggressive subpopulation characterized by conventional therapy escape.Key messagesCancer cells overexpress CAIX under transient and chronic extracellular acidosis.Acidosis-induced CAIX overexpression is NF-κB mediated and HIF-1α independent.FC16-670A prevents CAIX overexpression and induces acidified cancer cell death.

Targeting tumor-associated carbonic anhydrase IX in cancer therapy

Carbonic anhydrase IX: a new druggable target for the design of antitumor agents

Recent developments in targeting carbonic anhydrase IX for cancer therapeutics

Inhibition of carbonic anhydrase IX as a novel anticancer mechanism

Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one

Carbonic anhydrase IX inhibitors in cancer therapy: an update

Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors

Designing carbonic anhydrase inhibitors for the treatment of breast cancer

Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation

Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors

Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors

Carbonic anhydrase inhibition and the management of hypoxic tumors

Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis

Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX

Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic …

Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH

Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche

Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors